Ofatumumab retreatment and maintenance treatment in patients with CLL

Mise à jour : Il y a 4 ans
Référence : EUCTR2008-001507-39

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

To estimate the proportion of objective responders over 52 weeks to ofatumumab retreatment and maintenance treatment in patients with B-cell chronic lymphocytic leukemia (CLL)who progressed following response or stable disease after ofatumumab treatment in an ongoingclinical trial, Hx-CD20-406.


Critère d'inclusion

  • B-cell Chronic Lymphocytic Leukemia (CLL)